[{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair\u00ae Breezhaler\u00ae (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Heptares \/ Novartis"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,890.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Announces Second Novel Drug Candidate from Its Multi-Target Drug Discovery Collaboration with Pfizer has Started Clinical Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":1.8899999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.8899999999999999,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Pfizer"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Enerzair\u00ae Breezhaler\u00ae Approval in the European Union as a Treatment for Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Heptares \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Enerzair\u00ae Approval in Japan","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder for Capsule","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes that Enerzair\u00ae Breezhaler\u00ae has Been Recommended for Approval in the E.U for treating Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Heptares \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares and AbbVie Announce New Discovery Collaboration Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Sosei Heptares \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Aditum Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and Aditum Bio to Advance mGlu5 NAM Clinical Program for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"3-Chloro-5-[6-(5-Fluoropyridin-2-Yl)pyrimidin-4-Yl]benzonitrile","moa":"mGluR5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Aditum Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Aditum Bio"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"$10.0 million","newsHeadline":"Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"QP50ESO5RA","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0.38,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Biohaven","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ Biohaven"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$481.0 million","upfrontCash":"$44.0 million","newsHeadline":"Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPR35","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0.47999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ GlaxoSmithKline","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","amount":"$3,290.0 million","upfrontCash":"$125.0 million","newsHeadline":"Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Termination","leadProduct":"HTL0018318","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":3.29,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.29,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Allergan","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Allergan"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Metrion Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and Metrion Biosciences to collaborate on structure-based drug discovery approaches to ion channels","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Sosei Heptares","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Heptares \/ Sosei Heptares"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Formosa Laboratories","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sosei Heptares","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Eye Drop","sponsorNew":"Sosei Heptares \/ Formosa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Heptares \/ Formosa Pharmaceuticals"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"InveniAI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Sosei Heptares","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Heptares \/ Sosei Heptares"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"HTL0016878","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":2.7000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":2.7000000000000002,"dosageForm":"Oral Solution","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Funding","leadProduct":"SH-879","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Wellcome","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Wellcome"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Sosei Heptares\u2019 Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"HTL-0016878","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":2.7000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":2.7000000000000002,"dosageForm":"Capsule","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NBI-1117568","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Sosei Heptares","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Heptares \/ Sosei Heptares"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ University of Oxford"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares Receives $10 Million Milestone Payment in Discovery Collaboration with AbbVie Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Sosei Heptares \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$731.0 million","upfrontCash":"$37.0 million","newsHeadline":"Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Sosei Heptares","amount2":0.72999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.72999999999999998,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Heptares \/ Eli Lilly"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,280.0 million","upfrontCash":"$40.0 million","newsHeadline":"Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":1.28,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.28,"dosageForm":"","sponsorNew":"Sosei Heptares \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie Inc"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,890.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"PF-07081532","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sosei Heptares","amount2":1.8899999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1.8899999999999999,"dosageForm":"Tablet","sponsorNew":"Sosei Heptares \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Heptares \/ Pfizer Inc"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Provides Update on Lotiglipron Development","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lotiglipron","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sosei Heptares \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Heptares \/ Pfizer Inc"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Acquires Idorsia\u2019s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Clazosentan Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sosei Heptares \/ Sosei Heptares","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Heptares \/ Sosei Heptares"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Cancer Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I\/IIa Trial with Cancer Immunotherapy Drug HTL0039732","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sosei Heptares \/ Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Sosei Heptares \/ Cancer Research"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"NBI-1117570","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"PharmEnable","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ PharmEnable","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Heptares \/ PharmEnable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$1,026.0 million","upfrontCash":"$26.0 million","newsHeadline":"Sosei Heptares will Receive US$3.75 Million Payment in Multi-Target Partnership","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":1.03,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.03,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Genentech"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Gut-brain Axis Based Drug","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","amount":"$440.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Daridorexant HCl","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Sosei Heptares","amount2":0.44,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0.44,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Heptares \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Heptares \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"HTL0033744","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$732.5 million","upfrontCash":"$27.3 million","newsHeadline":"Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-In-Class Treatments Targeting All Symptoms of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"HTL0039732","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0.72999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.72999999999999998,"dosageForm":"Capsule","sponsorNew":"Sosei Heptares \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"NBI-1117569","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Sosei Heptares","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Sosei Heptares"}]
Find Clinical Drug Pipeline Developments & Deals by Sosei Heptares
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
